Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Nussenzweig: Clinical Trial of Broadly Neutralizing anti-HIV Antibodies |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2016-07-06 |
| Study Made Public: | 2019-05-20 |
Title
3BNC117 plus 10-1074 in HIV-negative individuals
Description
CAVD 583 (Protocol YCO-899) is a Phase 1 clinical trial evaluating safety and pharmacokinetics of the highly neutralizing anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 in healthy HIV-uninfected participants.
Sign in to see full information about this study and to download study data.
Products
Saline (non-specific) 3BNC117 10-1074Integrated data
PK MAb
Non-integrated data
Demographics (Supplemental)